These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 15231377)
1. No evidence for a reduction of myocardial infarctions by acarbose. van de Laar FA; Lucassen PL Eur Heart J; 2004 Jul; 25(13):1179; author reply 1179-80. PubMed ID: 15231377 [No Abstract] [Full Text] [Related]
2. [Robert Koch Award for acarbose. Antidiabetic drug prevents myocardial infarct]. MMW Fortschr Med; 2003 Feb; 145(6):59. PubMed ID: 12619367 [No Abstract] [Full Text] [Related]
3. [Does targeted therapy of type 2 diabetes prevent cardiovascular incidents?]. Leschke M Med Klin (Munich); 2003 Oct; 98 Suppl 1():12-6. PubMed ID: 14694836 [TBL] [Abstract][Full Text] [Related]
5. Intensive glucose lowering treatment in type 2 diabetes. Preiss D; Ray KK BMJ; 2011 Jul; 343():d4243. PubMed ID: 21791496 [No Abstract] [Full Text] [Related]
6. [Late diagnosis. Only after infarct is diabetes detected]. MMW Fortschr Med; 2004 Jan; 146(5):51. PubMed ID: 15035427 [No Abstract] [Full Text] [Related]
7. Acarbose for diabetes mellitus. Med Lett Drugs Ther; 1996 Feb; 38(967):9-10. PubMed ID: 8559114 [No Abstract] [Full Text] [Related]
8. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Hanefeld M; Cagatay M; Petrowitsch T; Neuser D; Petzinna D; Rupp M Eur Heart J; 2004 Jan; 25(1):10-6. PubMed ID: 14683737 [TBL] [Abstract][Full Text] [Related]
9. How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events? Freemantle N BMJ; 2005 Oct; 331(7520):836-8. PubMed ID: 16210286 [TBL] [Abstract][Full Text] [Related]
10. Randomized controlled trials remain fundamental to clinical decision making in Type II diabetes mellitus: a comment to the debate on randomized controlled trials (For debate). Richter B; Berger M Diabetologia; 2000 Apr; 43(4):528-32. PubMed ID: 10819251 [No Abstract] [Full Text] [Related]
11. The benefits of insulin therapy following acute myocardial infarction revisited. Soran H; Barzangy B; Younis N QJM; 2006 Sep; 99(9):635-7. PubMed ID: 16921196 [No Abstract] [Full Text] [Related]
12. Glucose-lowering therapy after myocardial infarction: more questions than answers. Radke PW; Schunkert H Eur Heart J; 2008 Jan; 29(2):141-3. PubMed ID: 18199566 [TBL] [Abstract][Full Text] [Related]
13. [Pioglitazone protects the type-2-diabetes patient from myocardial infarction and stroke]. MMW Fortschr Med; 2007 Aug; 149(31-32):52-3. PubMed ID: 17849787 [No Abstract] [Full Text] [Related]
17. [How does the PROactive Study change therapy of diabetes?]. Erdmann E MMW Fortschr Med; 2005 Oct; 147(41):6. PubMed ID: 16270501 [No Abstract] [Full Text] [Related]
18. [Prevention by life style intervention and medication. To run away from type 2 diabetes]. Wepner U MMW Fortschr Med; 2004 Apr; 146(14):16. PubMed ID: 15344745 [No Abstract] [Full Text] [Related]
19. US regulators relax restrictions on rosiglitazone. McCarthy M BMJ; 2013 Nov; 347():f7144. PubMed ID: 24286989 [No Abstract] [Full Text] [Related]
20. Miglitol and hepatotoxicity in type 2 diabetes mellitus. Carlson RF Am Fam Physician; 2000 Jul; 62(2):315, 318. PubMed ID: 10929699 [No Abstract] [Full Text] [Related] [Next] [New Search]